EQS-Adhoc: SHOP APOTHEKE EUROPE N.V.: Olaf Heinrich shall become the new CEO
|
EQS-Ad-hoc: SHOP APOTHEKE EUROPE N.V. / Key word(s): Personnel
SHOP APOTHEKE EUROPE N.V.: Olaf Heinrich shall become the new CEO
15-March-2023 / 18:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
SHOP APOTHEKE EUROPE N.V.: Olaf Heinrich shall become the new CEO
Sevenum, 15 March 2023. SHOP APOTHEKE EUROPE N.V. (SAE.DE), hereby announces that the supervisory board resolved today to propose Mr. Olaf Heinrich for election as member of the managing board and chairman of the managing board of the company at the next annual general meeting, which is expected to be held on 26 April 2023. It is intended that Mr. Olaf Heinrich will take office as a member of the managing board and chairman of the managing board on 1 August 2023 and will already be a consultant to the company in the period from 1 April 2023 to 31 July 2023.
15-March-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
|
| Language: |
English |
| Company: |
SHOP APOTHEKE EUROPE N.V. |
|
Erik de Rodeweg 11-13 |
|
5975 WD Sevenum |
|
Netherlands |
| Phone: |
0800 - 200 800 300 |
| Fax: |
0800 - 90 70 90 20 |
| E-mail: |
[email protected] |
| Internet: |
www.shop-apotheke-europe.com |
| ISIN: |
NL0012044747, DE000A19Y072 |
| WKN: |
A2AR94, A19Y07 |
| Indices: |
SDAX |
| Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: |
1583653 |
| |
| End of Announcement |
EQS News Service |
1583653 15-March-2023 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
| Umsatzerlöse1 |
283,99 |
539,71 |
701,01 |
968,06 |
1.060,32 |
1.204,35 |
1.798,76 |
| EBITDA1,2 |
-12,14 |
-15,56 |
-18,58 |
15,20 |
-38,73 |
-29,66 |
39,99 |
| EBITDA-Marge3 |
-4,27 |
-2,88 |
-2,65 |
1,57 |
-3,65 |
-2,46 |
|
| EBIT1,4 |
-19,20 |
-28,73 |
-33,45 |
-0,87 |
-65,70 |
-69,17 |
-17,30 |
| EBIT-Marge5 |
-6,76 |
-5,32 |
-4,77 |
-0,09 |
-6,20 |
-5,74 |
-0,96 |
| Jahresüberschuss1 |
-21,36 |
-33,61 |
-36,27 |
-16,77 |
-74,19 |
-77,65 |
-11,61 |
| Netto-Marge6 |
-7,52 |
-6,23 |
-5,17 |
-1,73 |
-7,00 |
-6,45 |
-0,65 |
| Cashflow1,7 |
-23,24 |
-23,54 |
-30,37 |
17,80 |
11,64 |
-29,11 |
61,46 |
| Ergebnis je Aktie8 |
-2,25 |
-2,79 |
-2,78 |
-1,17 |
-4,15 |
-4,32 |
-0,73 |
| Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Forvis Mazars
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| Redcare Pharmacy |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| A2AR94 |
143,000 |
Halten |
2.908,98 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 79,44 |
0,00 |
0,00 |
-68,49 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 5,57 |
47,33 |
1,62 |
76,84 |
| Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23
in % |
Hauptversammlung |
| 0,00 |
0,00 |
0,00 |
17.04.2024 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 25.04.2024 |
30.07.2024 |
05.11.2024 |
05.03.2024 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| 4,19% |
8,04% |
9,16% |
17,02% |
|
|
SHOP APOTHEKE EUROPE N.V. NL0012044747